A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer

MLA

Claudio Zamagni, et al. “A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy/Safety of Farletuzumab in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Women with Low CA-125 Platinum-Sensitive Ovarian Cancer.” Gynecologic Oncology, vol. 162, Aug. 2021, pp. S38–39. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5ad3b6847e7f855ffea3379994c1ccd4&authtype=sso&custid=ns315887.

APA

Claudio Zamagni, Susan Weil, Ignace Vergote, Giovanni Scambia, Yan Jia, Robert E. Coleman, Bradley J. Monk, Antonio González-Martín, Maria-Jesus Rubio, Jose Angel Arija, Hani Gabra, Rabbie K. Hanna, Lisa Ramsay, Keiichi Fujiwara, Kimio Ushijima, Deborah K. Armstrong, Thomas J. Herzog, Krishnansu S. Tewari, Christof Vulsteke, … Robert M. Wenham. (2021). A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer. Gynecologic Oncology, 162, S38–S39.

Chicago

Claudio Zamagni, Susan Weil, Ignace Vergote, Giovanni Scambia, Yan Jia, Robert E. Coleman, Bradley J. Monk, et al. 2021. “A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy/Safety of Farletuzumab in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Women with Low CA-125 Platinum-Sensitive Ovarian Cancer.” Gynecologic Oncology 162 (August): S38–39. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5ad3b6847e7f855ffea3379994c1ccd4&authtype=sso&custid=ns315887.